Quarterly ResultMay 12, 2026, 04:08 PM
Pharvaris Q1 Loss €39.2M; Cash €247M; Runway into 2028
AI Summary
Pharvaris reported a net loss of €39.2 million for the first quarter ended March 31, 2026, an improvement from the €46.3 million loss in the prior year period. The company maintained €247 million in cash and cash equivalents as of quarter-end, with a subsequent $132 million underwritten offering extending its cash runway into 2028. Key business updates include anticipated topline data from the CHAPTER-3 Phase 3 study in 3Q2026 and the New Drug Application submission for deucrictibant IR on-track for 1H2026.
Key Highlights
- Net loss for Q1 2026 was €39.2 million, an improvement from €46.3 million in Q1 2025.
- Basic and diluted loss per share was €0.60 for Q1 2026, down from €0.85 in Q1 2025.
- Cash and cash equivalents stood at €247 million as of March 31, 2026.
- A subsequent $132 million underwritten offering extends the cash runway into 2028.
- Research and development expenses were €30.2 million for Q1 2026.
- General and administrative expenses were €14.1 million for Q1 2026.
- Topline data from the pivotal Phase 3 CHAPTER-3 study is expected in 3Q2026.
- NDA submission for deucrictibant IR for on-demand HAE treatment remains on-track for 1H2026.